Invest in the Future of Protein Engineering
Tiragena Therapeutics offers investors exposure to a transformative platform technology addressing massive unmet medical needs in neurodegenerative diseases and aging—a combined market opportunity exceeding $50 billion.
Not an offer: This website is for general information only. It does not constitute an offer to sell or a solicitation to buy securities. Past performance of other companies or modalities does not predict Tiragena’s results.
Investment opportunity
- Multiple value inflection points: Phase I product launches; ADC partnership deals; preclinical data for protein editing; IND filings; clinical trial results.
- Experienced leadership: Prof. Budisa—pioneer in GCE, 100+ publications; Dr. Karbalaei-Heidari—protein engineering and commercialization experience.
- Strong intellectual property position: Platform technology (composition of matter, methods); therapeutic applications (disease-specific); delivery systems (VLP/LNP formulations); novel ncAA molecules.
Market opportunity analysis
Alzheimer’s disease
- Prevalence: 6.7M (US), 55M (worldwide)
- Current market: $5–10B (limited efficacy drugs)
- Economic burden: $355B/year in US alone
- Tiragena opportunity: First disease-modifying tau therapy
Parkinson’s disease
- Prevalence: 1M (US), 10M (worldwide)
- Current market: ~$5B (symptomatic only)
- No disease-modifying therapies approved
- Tiragena opportunity: Prevent α-synuclein aggregation
ALS
- Prevalence: 30K (US), 450K (worldwide)
- Current market: $1–2B
- Orphan drug pricing: $200K–500K/patient/year
- Median survival: 3–5 years from diagnosis
- Tiragena opportunity: Slow progression, extend survival
Age-related macular degeneration
- Prevalence: 11M (US) dry AMD
- Current therapies: None approved for dry AMD
- Wet AMD market (anti-VEGF): $10B
- Tiragena opportunity: First therapy for geographic atrophy
Risk factors & mitigation (summary)
Technical risks: Delivery efficiency (CNS)—medium probability; mitigation: multiple delivery platforms (VLP + LNP), intrathecal backup. Immunogenicity—medium; mitigation: pseudouridine-modified mRNA, extensive preclinical testing. Protein editing efficiency—low–medium; mitigation: dose optimization, multiple ncAA options.
Regulatory risks: Novel mechanism pathway—medium; mitigation: early FDA engagement, mRNA precedent, orphan drug designations. Long-term safety concerns—medium; mitigation: extended monitoring, patient registries, reversible approach.
Commercial risks: Market acceptance—medium; mitigation: strong safety story, patient advocacy, health economics data. Reimbursement—medium; mitigation: cost-effectiveness analysis, real-world evidence. Competition—medium; mitigation: platform advantages, strong IP, multiple indications.
Partnership & exit strategy
Near-term (Phase I–II): ADC platform licensing; research product distribution agreements; co-development partnerships.
Mid-term (Phase II–III): ADC out-licensing (post–Phase I data); protein editing platform partnerships; regional commercialization deals.
Governance & reporting
Board composition: Founder representation; independent directors (industry, clinical, finance expertise); investor observers (major stakeholders).
Investor rights: Information rights (quarterly financials, annual budgets); pro-rata rights (future rounds); board observation rights (major investors); anti-dilution protection (weighted average).
Reporting: Quarterly financial statements; annual strategic reviews; regular milestone updates; access to management.
Why invest now?
- Platform validated: 20+ years development, 100+ publications
- Clear path to revenue: Phase I products launching Year 1
- Multiple shots on goal: Three-phase approach, multiple indications
- Favorable market timing: mRNA validated, neuroscience investment strong
- Experienced team: Proven scientific leadership
- Strong IP position: Patents pending, trade secrets established
- Early-stage valuation: Pre-revenue pricing with near-term milestones
Next 12–18 month catalysts: First product launches; initial customer traction; patent allowances; ADC partnership discussions; Series A fundraising; expanded team and capabilities.
Investor resources
Due diligence materials: Detailed scientific presentations; financial models and projections; IP portfolio documentation; market analysis reports; management team CVs; reference calls with scientific advisors.
Contact: info@tiragena.com
Investment deck: Request the latest investor presentation at info@tiragena.com.
Data room access: Available for qualified investors under NDA.
Frequently asked questions
What makes Tiragena different from gene editing companies?
We edit proteins, not genes—using transient mRNA rather than permanent DNA changes. This is safer, reversible, and addresses different disease mechanisms (preventing aggregation vs. correcting mutations).
How does the three-phase model reduce risk?
Phase I generates revenue to extend runway. Phase II partnerships provide validation and capital. Phase III builds on proven technology with multiple indications reducing single-asset risk.
What is your IP position?
We have patent applications covering: (1) Platform technology (GCE methods, compositions), (2) Therapeutic proteins (ncAA-modified tau, α-synuclein, etc.), (3) Delivery systems (VLP/LNP), (4) Disease applications. Trade secrets protect manufacturing processes.
When do you expect partnerships?
Phase I product partnerships (distributors): Year 1–2. ADC partnerships: Year 3–4. Protein editing partnerships: Year 6–8.
What is the expected timeline to exit?
Most likely acquisition Year 8–10 after Phase I/II clinical data. IPO possible Year 6–8 if multiple programs advancing.
How much capital will be needed total?
Seed: $1.5–2M, Series A: $5–8M, Series B: $15–25M. Total ~$25–35M to Phase II readout. Partnerships expected to fund Phase III development.
Who are comparable investments?
Beam Therapeutics, Prime Medicine, Verve Therapeutics (editing), Denali Therapeutics (neuroscience), Alnylam (mRNA precedent), Seagen (ADC precedent).
Qualified investors: start with a short note to info@tiragena.com.